4.7 Article

Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management

Journal

Publisher

ENDOCRINE SOC
DOI: 10.1210/clinem/dgad153

Keywords

cholesterol; lipoproteins; cardiovascular disease; statins; statin resistance; patient management

Ask authors/readers for more resources

This article introduces the lipid-lowering therapy of statins in the prevention of atherosclerotic cardiovascular disease (ASCVD), but their effectiveness in lowering LDL-C can vary significantly between individuals. The different causes of a suboptimal statin response are described, and an algorithm for the diagnosis and clinical management of these patients is provided.
Context Statins are the lipid-lowering therapy of choice for the prevention of atherosclerotic cardiovascular disease (ASCVD) but their effectiveness in lowering low-density lipoprotein cholesterol (LDL-C) can substantially differ between individuals. In this mini-review, we describe the different causes for a suboptimal statin response and an algorithm for the diagnosis and clinical management of these patients. Evidence Acquisition A PubMed search using the terms statin resistance, statin sensitivity, statin pharmacokinetics, cardiovascular disease, and lipid-lowering therapies was performed. Published papers in the past 10 years that were relevant to the topic were examined to provide content for this mini-review. Evidence Synthesis Suboptimal lowering of LDL-C by statins is a major problem in the clinical management of patients and limits the value of this therapeutic approach. There are multiple causes of statin hyporesponsiveness with compliance being the most common explanation. Other causes, such as analytical issues with LDL-C measurement and the presence of common lipid disorders (familial hypercholesterolemia, elevated lipoprotein[a] and secondary dyslipidemias) should be excluded before considering primary statin resistance from rare genetic variants in lipoprotein-related or drug-metabolism genes. A wide variety of nonstatin lipid-lowering drugs are now available and can be added to statins to achieve more effective LDL-C lowering. Conclusions The evaluation of statin hyporesponsiveness is a multistep process that can lead to the optimization of lipid-lowering therapy for the prevention of ASCVD. It may also lead to the identification of distinct types of dyslipidemias that require specific therapies and/or the genetic screening of family members.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available